Heated debate in Montana committee over bill to give chiropractors optional limited prescriptive authority

Representative Greg Oblander introduced House Bill 929 as an opt‑in endorsement that would permit chiropractors who meet board-defined education and training requirements to prescribe a narrowly defined formulary for musculoskeletal care, including nonsteroidal anti-inflammatory drugs (NSAIDs), certain muscle relaxants, topical analgesics and short courses of corticosteroids.

Oblander emphasized choice for practitioners and said the Montana Department of Labor and Industry and the chiropractic licensing board would adopt rules to define educational requirements and oversight. "This is a choice. There is nothing compulsory in this bill," Oblander told the committee, adding that the board would establish the qualifications necessary for the endorsement and that the department would oversee rulemaking.

Supporters — primarily chiropractors and allied clinicians from across Montana and elsewhere — argued the endorsement would ease delays in care, especially in underserved and rural areas. Proponents described clinical examples in which patients waited days for a primary-care appointment or emergency‑department visit and said a limited ability to provide short‑term medication would allow timely, integrated care without replacing hands‑on chiropractic treatment. Remote witnesses and out‑of‑state practitioners from New Mexico and Idaho described their states’ experiences and said malpractice rates did not rise in their practices; several proponents asserted prescribing would be rare in routine chiropractic care.

Opposition at the hearing was large and sustained. Dozens of Montana chiropractors, representatives of chiropractic organizations (including the International Chiropractors Association), malpractice insurers and the Montana Medical Association urged the committee to reject the bill or send it back for further study. Opponents raised three central concerns: (1) the bill places oversight solely with the chiropractic licensing board as written and does not statutorily require medical or pharmacy-board participation; (2) chiropractic education does not include the depth of clinical pharmacology and supervised clinical training opponents say is necessary for safe prescribing; and (3) multiple malpractice insurers warned that expanding scopes of practice could increase premiums and litigation risk.

Jean Branscum, CEO of the Montana Medical Association, told the committee the group opposed the bill on patient-safety grounds and because the bill as drafted lacks physician‑or pharmacist‑linked oversight mechanisms many other scope‑expansion efforts include. Bureau chief Kevin Bragg and Commissioner Sarah Swanson described how rulemaking would proceed under Title 37, noted the board has statutory authority to set education requirements, and said any implementation costs for a new endorsement would be borne by the chiropractic licensing fund. Swanson summarized the typical implementation steps — board rulemaking with interested‑party notice, public hearings and DLI oversight — and noted the department’s preliminary estimate for rulemaking and IT implementation costs in its fiscal note.

The hearing recorded extensive testimony on both sides and multiple requests for more concrete rulemaking language (for example, minimum supervised clinical hours, a defined pharmacology curriculum and explicit cross‑board oversight). Representative Oblander closed by urging the committee to give the bill a due pass; the transcript records no committee vote during the hearing.

If the committee advances HB 929, the next steps would be rulemaking by the Board of Chiropractors with Department of Labor and Industry oversight to define the endorsement’s educational requirements, clinical supervision expectations and any required collaborative or oversight arrangements with other licensing boards.